Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05429320 · ClinicalTrials.gov registry record · Phase 2
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT05429320: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05429320 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05429320, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.
Interventions
- PROCEDURE Local ablative therapy
- OTHER Blood collection to assess for ctDNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2026-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05429320
The ClinicalTrials.gov registry entry for NCT05429320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Local ablative therapy is the first listed.
NCT05429320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05429320 about?
NCT05429320 is a clinical study titled "A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.
What is the current status of trial NCT05429320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2022-06-15. Estimated completion is 2026-01-28.
What interventions are being tested in trial NCT05429320?
The interventions under investigation include: Local ablative therapy (PROCEDURE), Blood collection to assess for ctDNA (OTHER).
Who is sponsoring clinical trial NCT05429320?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.